New pill for rare bone disease enters human testing
Disease control
Recruiting now
This study tests a new oral drug called ALE1 for hypophosphatasia (HPP), a rare bone disease. It is the first time this drug is given to humans, so the main goal is to check its safety and how the body processes it. The trial includes healthy adults and adults with HPP, and some …
Phase: PHASE1, PHASE2 • Sponsor: Alesta Therapeutics • Aim: Disease control
Last updated May 17, 2026 18:42 UTC